Cellpoint BV
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cellpoint BV - overview
Established
2018
Location
Oegstgeest, -, Netherlands
Primary Industry
Biotechnology
About
Based in Oegstgeest, Netherlands, and founded in 2018, Cellpoint BV operates as a biotechnology company that enables clinicians to treat cancer by retargeting patient immune cells at the point of care. In June 2022, Galapagos NV, a biotechnology company specialized in the discovery and development of small molecule medicines acquired CellPoint NV. As of July 2022, the company is led by its CEO Dr. Tol Trimborn.
Cellpoint BV offers end-to-end workflow management and monitoring software that treats hematological malignancies by retargeting patient immune cells. The company has developed CAR-T therapies and a 6-day manufacturing process, powered by its proprietary xCellit monitoring software system. The company also provides the Cocoon™ platform, a fully closed and automated manufacturing device, a kit comprising CAR-T reagents, and full training and support.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.cellpoint.bio
Verticals
HealthTech, Manufacturing
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.